India’s Drug Regulator Flags 169 “Not of Standard Quality” Samples in April, One Batch Declared Spurious — What Patients and Clinicians Need to Know

NEW DELHI — The Central Drugs Standard Control Organization (CDSCO) reported in May 2026 that routine quality testing in April identified 169 drug samples as “Not of Standard Quality” (NSQ) and one batch as spurious. Following extensive laboratory analysis across central and state testing facilities in India, regulators confirmed that investigations and targeted recalls are actively underway. These measures aim to protect patients and swiftly remove affected lots from the national pharmaceutical supply chain.

Inside the Findings: Widely Used Medications Impacted

The scale of the April surveillance bulletin highlights the expansive nature of India’s regulatory safety net. Of the 169 NSQ samples, 42 were detected by central drug testing laboratories, while state drug testing laboratories identified 127.

Crucially, the findings do not target niche or rare pharmaceuticals. Instead, the NSQ list includes highly common, everyday therapeutic classes found in millions of households:

• Analgesics: Paracetamol batches used for pain and fever relief.

• Metabolic Health: Metformin and various antidiabetic combinations prescribed for type 2 diabetes management.

• Antibiotics: Amoxicillin formulations used to treat bacterial infections.

• Respiratory Care: Common cough syrups.

In addition to the NSQ samples, regulators issued a critical alert for a single batch of Ursodeoxycholic Acid—a medication primarily used to treat chronic gallbladder and liver diseases. Sampled from Bihar, this specific batch was preliminarily flagged as spurious. The action was triggered after the labeled manufacturer stated they had not produced that particular lot, pointing toward a case of mislabeling or counterfeiting.

Defining the Terms: NSQ vs. Spurious

For patients and healthcare providers, understanding the exact regulatory terminology is essential to properly assessing risk without causing panic.

Not of Standard Quality (NSQ): This designation means the tested sample failed to meet strict pharmacopoeial specifications for strength, purity, or quality. It can occur due to manufacturing variances, degradation during transport, or improper storage conditions.

Spurious: Under Section 17B of India’s Drugs and Cosmetics Act, a drug is deemed spurious if it is counterfeit, deliberately misrepresented, or falsely labeled to deceive consumers and regulators regarding its origin and identity.

The Regulatory Response Framework

Under the statutory provisions of India’s Drugs and Cosmetics Act, an NSQ or spurious declaration initiates an immediate regulatory chain reaction. The CDSCO issues formal recall directions and stop-distribution orders directly to the respective manufacturing licensees and local state regulators.

To ensure transparency, the CDSCO publishes these monthly drug alerts directly to its public portal. This allows hospitals, pharmacists, and supply chain managers to cross-reference their current inventory and immediately isolate compromised batches.

Independent public health experts note that these spot-detections are evidence of an active regulatory apparatus rather than a systemic breakdown.

“Spot-detection of NSQ samples is an expected part of a functioning regulatory system—it shows the surveillance net is working,” explained an independent pharmaceutical quality specialist familiar with CDSCO procedures. “However, every single NSQ finding must trigger a robust traceback investigation and manufacturer accountability to permanently close vulnerabilities and prevent patient harm.”

Public Health Implications and Patient Safety

The direct risk to an individual patient taking an NSQ medication depends heavily on why the sample failed. A product with reduced active pharmaceutical ingredients (API) may exhibit sub-therapeutic effectiveness, meaning a patient’s infection or high blood sugar might not be adequately controlled. Conversely, unexpected impurities or incorrect strengths could cause unexpected side effects or adverse reactions. Spurious medications carry an even higher risk profile because their true ingredients and manufacturing origins are entirely unverified.

Despite these risks, health authorities stress the importance of system-level reassurance. These regulatory findings are strictly batch-specific. The presence of an NSQ sample does not mean that an entire brand, medication line, or therapeutic class is unsafe or ineffective. It simply means that a single, specific production lot failed to meet the required mark.

Limitations of Routine Surveillance

While routine market sampling is highly effective, it features inherent operational limitations. Because regulators perform random testing on selected batches, surveillance nets cannot guarantee the capture of every substandard lot in commerce.

Conversely, a single NSQ identification is not definitive proof of widespread quality failures across a manufacturer’s entire operation; it serves as a statistical flare indicating that a targeted, deeper investigation is required.

For public health communication, balancing transparency with public stability is delicate. Regulators must publish clear, actionable information so that clinicians and consumers can verify their specific lot numbers without causing patients to abruptly halt vital, life-saving medication regimes out of unguided fear.

Practical Guidance for Clinicians, Pharmacists, and Patients

For Healthcare Professionals & Pharmacists

• Inventory Auditing: Review current pharmacy stock against the specific batch numbers and manufacturing dates published in the April CDSCO drug alert bulletin.

• Quarantine Protocol: Immediately isolate any matching lots and halt dispensing, following the standard stop-distribution guidelines.

• Adverse Reporting: Report any unexpected therapeutic failures or unusual adverse reactions to the national pharmacovigilance network.

For Patients

• Check Your Labels: Look at the strip or bottle of your medication to locate the Batch Number (B.No.) and Expiry Date. Compare these with official state or central drug alerts.

• Do Not Abruptly Stop Treatment: If you take medication for chronic conditions like diabetes or bacterial infections, do not stop taking your medicine out of anxiety. Stopping essential therapies abruptly poses an immediate health risk.

• Consult Professionals: If you suspect your medication is not working as intended, or if you experience unexpected symptoms, consult your prescribing doctor or pharmacist immediately to arrange for an alternative batch or brand.

Policy and Industry Trajectory

The recurring detection of NSQ batches in routine monthly bulletins underscores an ongoing need for structural tightening across the pharmaceutical industry. Experts point out that strengthening cold-chain logistics, enforcing stricter Good Manufacturing Practices (GMP) compliance, and improving end-to-end supply chain traceability are vital steps to reducing degradation during transit.

While monthly public listings by the CDSCO successfully empower the public and pharmacists to act quickly, long-term public trust in the medicine supply relies heavily on the transparency of the subsequent investigations. Visible enforcement actions and public disclosure of why a batch failed will ensure that India’s domestic pharmaceutical supply remains secure, resilient, and safe for all.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Central Drugs Standard Control Organization (CDSCO). NSQ Alerts and Monthly Drug Alert Page, Government of India. Available: Alerts – CDSCO.